Clonal hypereosinophilia

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Retrieved on: 
Wednesday, July 14, 2021
Enzymes, Chemical compounds, Branches of biology, Tyrosine kinase receptors, Leukemia, Protein kinase inhibitors, CD135, Cyclin-dependent kinase 8, Tumors of the hematopoietic and lymphoid tissues, Acute myeloid leukemia, Myeloid leukemia, Clonal hypereosinophilia

Following the completion ofthe75mg cohort, the data generated will be reviewed by the agency and a further dose escalation strategy will be established.

Key Points: 
  • Following the completion ofthe75mg cohort, the data generated will be reviewed by the agency and a further dose escalation strategy will be established.
  • The partial clinical hold was issued following Ryvu's recent report to the FDA of a Serious Adverse Event (SAE) involving a patient death that may possibly be related to RVU120.
  • RVU120 is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase 1b clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
  • SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia.

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Medical specialties, Stem cells, Biotechnology, Immune system, Lymphocytes, Natural killer cell, Hematopoietic stem cell, Myelodysplastic syndrome, Clonal hypereosinophilia

MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.

Key Points: 
  • MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.
  • Current treatments, including chemotherapy and bone marrow/stem cell transplantation, have varying degrees of success, and there is no known cure for MDS.
  • In the lab we have shown that INKmune binds to multiple NK receptors and initiates the activation of over 3000 genes associated with function, trafficking, proliferation and survival.
  • No single cytokine in our hands has such broad, physiological effects, which has inspired us to refer to INKmune as a pseudokine.

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

Retrieved on: 
Monday, October 19, 2020
RTT, Tumors of the hematopoietic and lymphoid tissues, Acute myeloid leukemia, Cancer, Chronic lymphocytic leukemia, CD135, Leukemia, Oncology, Branches of biology, Clinical medicine, Entospletinib, Clonal hypereosinophilia

The investigational drug is the only known clinical agent that potently inhibits both FLT3 and BTK, giving it broad therapeutic potential across the spectrum of lymphoid and myeloid hematologic malignancies.

Key Points: 
  • The investigational drug is the only known clinical agent that potently inhibits both FLT3 and BTK, giving it broad therapeutic potential across the spectrum of lymphoid and myeloid hematologic malignancies.
  • Separate from the AML trial, Aptose is conducting a Phase 1 a/b dose escalation study with CG-806 in patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkins lymphomas (NHL), who have failed or are intolerant to current therapies.
  • Acute myeloid leukemia, or AML, is a heterogeneous and aggressive cancer of the bone marrow and blood that occurs in people of all ages, but is most common in adults older than 65.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Prelude Therapeutics Secures $60 Million and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer

Retrieved on: 
Wednesday, June 12, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Branches of biology, Medicine, Medical specialties, Tumors of the hematopoietic and lymphoid tissues, Lymphoma, Apoptosis, Clonal hypereosinophilia, Hedgehog pathway inhibitors

PRMT5 plays an important role in several cellular processes that drive cancer cell proliferation, cell cycle progression and resistance to apoptosis in hematological malignancies and solid tumors.

Key Points: 
  • PRMT5 plays an important role in several cellular processes that drive cancer cell proliferation, cell cycle progression and resistance to apoptosis in hematological malignancies and solid tumors.
  • Proceeds from the Series B financing will be used to advance Preludes proprietary PRMT5 inhibitor, PRT543, through proof of concept clinical studies.
  • PRT543 is in a parallel dose escalation Phase 1 clinical trial for solid tumors, myeloid malignancies and lymphomas.
  • Prelude is focused on the discovery and development of small molecule agents targeting novel molecular mechanisms that drive cancer cell growth, survival and resistance to current treatments.

Leukemia Therapeutics Market Worth $17.1 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, May 27, 2019
RTT, Cancer, Leukemia, Medicine, Medical specialties, Pediatric cancers, Lymphoma, FIP1L1, Clonal hypereosinophilia

A large number of small-molecule drugs have also been approved, which is expected to drive the market growth.

Key Points: 
  • A large number of small-molecule drugs have also been approved, which is expected to drive the market growth.
  • North America holds the largest share of the Leukemia Therapeutics Market, by region.
  • The rising number of leukemia patients, tissue engineering, new drugs & therapies launches, and high research funding for the treatment of leukemia are the major driving factors in this market.
  • In 2018, according to the Leukemia & Lymphoma Society, an estimated 381,774 people were living with or in remission from leukemia in the US.

Leukemia Therapeutics Market Worth $17.1 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, May 27, 2019
RTT, Cancer, Leukemia, Medicine, Medical specialties, Pediatric cancers, Lymphoma, FIP1L1, Clonal hypereosinophilia

A large number of small-molecule drugs have also been approved, which is expected to drive the market growth.

Key Points: 
  • A large number of small-molecule drugs have also been approved, which is expected to drive the market growth.
  • North America holds the largest share of the Leukemia Therapeutics Market, by region.
  • The rising number of leukemia patients, tissue engineering, new drugs & therapies launches, and high research funding for the treatment of leukemia are the major driving factors in this market.
  • In 2018, according to the Leukemia & Lymphoma Society, an estimated 381,774 people were living with or in remission from leukemia in the US.